Last reviewed · How we verify
BR101801
At a glance
| Generic name | BR101801 |
|---|---|
| Also known as | Bosmolisib |
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. (PHASE2)
- BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BR101801 CI brief — competitive landscape report
- BR101801 updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI